2019 Antibody Drug Conjugate Market Top 10 Players as eattle Genetics (U.S.), ImmunoGen, Roche Holding AG, Antikor, Immunomedics, Pfizer, Celldex Therapeutics, Millennium Pharmaceuticals, AbbVie, etc

As per the analysis of Market Research Future (MRFR), the Growth of the Global Antibody Drug Conjugate Market is perceived to be healthy and is expected to garner high growth revenue in the coming years.

Antibody Drug Conjugate Market - Scenario

Global Antibody Drug Conjugate Market is set to proliferate saliently at a CAGR of 19% during the forecast period 2017 to 2023. These drug conjugates are regarded as the new age of therapeutic agents. The efficiency of the drug in treating diseases has propelled demand in the global market, and the trend is likely to perpetuate over the next few years.

Increased investments in research & developments in the antibody drug conjugate market are further expected to augment the market size. Nevertheless, the high cost associated with the procedures is likely to hold the market growth through the projection period.

The effects of targeting specific cells coupled with the killing ability of cytotoxic drugs make this antibody drug conjugate the ideal choice for the treatment of various cancers. The rising prevalence of cancer all across the globe has catapulted the antibody drug conjugate market on an upward trajectory. Additionally, the advancements in medical technologies are anticipated to drive the growth of the global market by enhancing the accuracy of the drug.

Request Sample Copy at https://www.marketresearchfuture.com/sample_request/1113

Segmentation:

By type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.

By application, the antibody drug conjugate market has been segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further sub-segmented into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).

By product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.

By technology, the antibody drug conjugate market has been segmented into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.

By end-user, the global antibody drug conjugate market is segmented into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others. 

Regional Analysis:

By region, the global antibody drug conjugate market is segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas dominate the global market owing to technological innovations, manufacturing process advancements, the contribution of nanotechnology, etc. Led by the U.S., the region is anticipated to retain its pole position through the assessment period. Europe is likely to retain its second spot trailed by the Asia Pacific which is an emerging market for antibody drug conjugate.

Vital Players:

Some of the key players profiled by MRFR are Seattle Genetics (U.S.), ImmunoGen, Inc. (U.S.), Roche Holding AG (Switzerland), Antikor (U.K.), Immunomedics (U.S.), Pfizer Inc. (U.S.), Celldex Therapeutics (U.S.), Millennium Pharmaceuticals (U.S.), AbbVie Inc. (U.S.), Genentech (U.S.), Concortis Biotherapeutics (U.S.), Agensys, Inc. (U.S.),  Bayer HealthCare (Germany),  Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (U.S.), Heidelberg Pharma (Germany), Oxford BioTherapeutics (U.S.), Mersana Therapeutics (U.S.), and Synthon (U.S.).

Browse Complete 140 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113

Some Points from TOC of Antibody Drug Conjugate Market Research Report – Forecast to 2023:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

TOC CONTINUED…

LIST OF TABLES:

Table 1 Antibody Drug Conjugate Industry Synopsis, 2017–2023

Table 2 Antibody Drug Conjugate Market Estimates & Forecast, 2017–2023, (USD Million)

Table 3 Antibody Drug Conjugate Market, By Region, 2017–2023, (USD Million)

Table 4 Antibody Drug Conjugate Market, By Type, 2017–2023, (USD Million)

Table 5 Antibody Drug Conjugate Market, By Application, 2017–2023, (USD Million)

Table 6 Antibody Drug Conjugate Market, By Product, 2017–2023, (USD Million)

Table 7 Antibody Drug Conjugate Market, By Technology, 2017–2023, (USD Million)

Table 8 Antibody Drug Conjugate Market, By End-User, 2017–2023, (USD Million)

Table 9 North America Antibody Drug Conjugate Market, By Type, 2017–2023, (USD Million)

Table 10 North America Antibody Drug Conjugate Market, By Application, 2017–2023, (USD Million)

TOC CONTINUED…!

Ask Any Question at https://www.marketresearchfuture.com/enquiry/1113

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.